Tag Archive for: clinical trial

Viking Therapeutics announced Tuesday that its GLP-1/GIP receptor dual agonist helped patients lose up to nearly 15% of their weight over about three months in a Phase II study.

On the heels of Takeda’s $300 million licensing deal for rusfertide, Protagonist Therapeutics’ peptide mimetic lowered hematocrit levels in patients with polycythemia vera, a type of blood cancer.

After treatment with a CD19 CAR-T therapy, patients with systemic lupus erythematosus, idiopathic inflammatory myositis or systemic sclerosis achieved long-lasting remission, according to results published in the NEJM.

Rapt Therapeutics said on Tuesday the U.S. FDA had placed on hold two mid-stage trials of the company’s drug to treat eczema and asthma, after liver failure was observed in one of the patients.

While the company did not provide specific reasons for the halt, Gilead Sciences said it is “reviewing the benefit-risk” of its anti-CD47 antibody magrolimab across all ongoing trials.

CSL on Sunday announced that its investigational cholesterol efflux enhancer CSL112 failed the Phase III AEGIS-II trial, unable to significantly improve outcomes in patients who had suffered a heart attack.

The company’s three-drug combination met all primary and key secondary endpoints in two randomized controlled trials in cystic fibrosis patients, paving the way for an application to regulators.

Yesterday the company posted findings from an interim analysis of the Phase III DREAMM-7 trial showing that its antibody-drug conjugate Blenrep, when used in a three-drug regimen, led to a significant improvement in progression-free survival in patients with relapsed or refractory multiple myeloma.

The biotech is taking a synergistic approach to obesity with two muscle-preserving antibodies set to enter a Phase II study in mid-2024 in combination with existing incretin-based treatments.

The drug, nipocalimab, significantly reduced disease symptoms in a late-stage study with adult patients having myasthenia gravis, a chronic neuromuscular disorder that causes weakness in the voluntary muscle, the company announced.